Search Results | Cancer Research | American Association for Cancer Research

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Abstract LB108: Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy

Naveen Pemmaraju, Jacqueline Garcia, Jalaja Potluri, Yan Sun, Jason Harb, Srinivas K. Tantravahi, Srdan Verstovsek, Claire Harrison

Cancer Res (2022) 82 (12_Supplement): LB108.

DOI: https://doi.org/10.1158/1538-7445.AM2022-LB108

Published: 15 June 2022

View article

Journal Articles

Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Stephen T. Oh, Jean-Jacques Kiladjian, Francesca Palandri, Jason R. Gotlib, Sanjay Mohan, Haris Ali, Ekatherine Asatiani, Francis Seguy, Feng Zhou, Srdan Verstovsek

Cancer Res (2021) 81 (13_Supplement): CT216.

DOI: https://doi.org/10.1158/1538-7445.AM2021-CT216

Published: 01 July 2021

View article

Journal Articles

Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models

Cancer Res (2020) 80 (16_Supplement): 2915.

DOI: https://doi.org/10.1158/1538-7445.AM2020-2915

Published: 15 August 2020

View article

Journal Articles

Abstract 4912: A snapshot of myeloproliferative neoplasms in the United States: Analysis of the “myMPN” patient registry

Robyn M. Scherber, Lindsey Whyte, Michelle Woehrle, Claire Harrison, John Mascarenhas, Srdan Verstovsek, Alison Moliterno, Ruben A. Mesa

Cancer Res (2019) 79 (13_Supplement): 4912.

DOI: https://doi.org/10.1158/1538-7445.AM2019-4912

Published: 01 July 2019

View article

Journal Articles

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Christopher P. Mill, Joseph D. Khoury, Srdan Verstovsek, Kapil N. Bhalla

Cancer Res (2019) 79 (13_Supplement): 3836.

DOI: https://doi.org/10.1158/1538-7445.AM2019-3836

Published: 01 July 2019

View article

Journal Articles

Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement

Srdan Verstovsek, Alessandro Rambaldi, Ekaterine Asatiani, Christine F. Lihou, Huiling Zhen, Andreas Hochhaus

Cancer Res (2017) 77 (13_Supplement): CT057.

DOI: https://doi.org/10.1158/1538-7445.AM2017-CT057

Published: 01 July 2017

View article

Journal Articles

Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Dyana T. Saenz, Warren C. Fiskus, Kanak Raina, Taghi Manshouri, Kevin G. Coleman, Yimin Qian, Andrew P. Crew, Angela Shen, Christopher P. Mill, Baohua Sun, Misun Kim, Agnieszka J. Nowak, Srdan Verstovsek, Craig M. Crews, Kapil N. Bhalla

Cancer Res (2017) 77 (13_Supplement): 5067.

DOI: https://doi.org/10.1158/1538-7445.AM2017-5067

Published: 01 July 2017

View article

Journal Articles

Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML)

Cancer Res (2016) 76 (14_Supplement): 3205.

DOI: https://doi.org/10.1158/1538-7445.AM2016-3205

Published: 15 July 2016

View article

Journal Articles

Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells

Dyana T. Saenz, Warren C. Fiskus, Taghi Manshouri, Jing Lu, Yimin Qian, Kanak Raina, Baohua Sun, Stephanie S. Krieger, Simrit Parmar, Srdan Verstovsek, Kapil N. Bhalla

Cancer Res (2016) 76 (14_Supplement): 4699.

DOI: https://doi.org/10.1158/1538-7445.AM2016-4699

Published: 15 July 2016

View article

Journal Articles

Bone Marrow Stroma–Secreted Cytokines Protect JAK2^V617F-Mutated Cells from the Effects of a JAK2 Inhibitor

Taghi Manshouri, Zeev Estrov, Alfonso Quintás-Cardama, Jan Burger, Ying Zhang, Ana Livun, Liza Knez, David Harris, Chad J. Creighton, Hagop M. Kantarjian, Srdan Verstovsek

Cancer Res (2011) 71 (11): 3831–3840.

DOI: https://doi.org/10.1158/0008-5472.CAN-10-4002

Published: 31 May 2011

View article

Includes: Supplementary data

Journal Articles

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

Omar Abdel-Wahab, Taghi Manshouri, Jay Patel, Kelly Harris, JinJuan Yao, Cyrus Hedvat, Adriana Heguy, Carlos Bueso-Ramos, Hagop Kantarjian, Ross L. Levine, Srdan Verstovsek

Cancer Res (2010) 70 (2): 447–452.

DOI: https://doi.org/10.1158/0008-5472.CAN-09-3783

Published: 13 January 2010

View article

Includes: Supplementary data

Journal Articles

Structure-based drug design of c-kit inhibitors for use in the treatment of several types of cancer

David Maxwell, Ashutosh Pal, Zhenghong Peng, Alexandr Shavrin, Stefan Faderl, Davis Harris, Quin Van, Liu Zhiming, Srdan Verstovsek, Taghi Manshouri, Alessandra Ferrajoli, Hagop Kantarjian, Zeev Estrov, Eylem Ozturk, Angelo Sanguino, Gabriel Lopez-Berestein, William Bornmann

Cancer Res (2007) 67 (9_Supplement): 3959.

Published: 01 May 2007

View article

Journal Articles

Expression analysis of the p15^INK4B and p21^Cip/WAF genes in patients with MDS treated with decitabine

Yasuhiro Oki, Hagop M. Kantarjian, Jan Davis, Farhad Ravandi, Srdan Verstovsek, Jorge E. Cortes, Guillermo Garcia-Manero, Jean-Pierre Issa

Cancer Res (2006) 66 (8_Supplement): 540.

Published: 15 April 2006

View article

Journal Articles

EXEL-0862, a novel tyrosine kinase inhibitor, inhibits KIT activation and induces apoptosis in human mast cells bearing mutated codon 816 c-kit in vitro and ex vivo: Therapeutic implications

Jingxuan Pan, Hagop M. Kantarjian, Manshouri Taghi, Cem Akin, Peter Lamb, Jorge E. Cortes, Francis J. Giles, Srdan Verstovsek

Cancer Res (2006) 66 (8_Supplement): 952.

Published: 15 April 2006

View article

Journal Articles

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in adult patients (pts) with imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

Francis J. Giles, Oliver Ottmann, Jorge Cortes, Barbara Wassman, Lydia Wunderle, Susan O’Brien, Dan Jones, Andreas Hochhaus, Srdan Verstovsek, Patricia Rae, Kristine Rose, Leila Alland, Margaret Dugan, Paul Manley, Miloslav Beran, Maher Albitar, Hagop Kantarjian

Cancer Res (2005) 65 (9_Supplement): 935.

Published: 01 May 2005

View article

Journal Articles

Cloretazine™, a novel sulfonylhydrazine alkylating agent, combined with cytarabine is an active regimen in patients with refractory hematologic malignancies

Francis J. Giles, Susan O’Brien, Srdan Verstovsek, Jorge Cortes, Debra Thomas, Stephan Faderl, Alessandra Ferrajoli, Farhad Ravandi-Kashani, Steven Kornblau, Guillermo Garcia-Manero, Ann Cahill, Mario Sznol, Hagop Kantarjian

Cancer Res (2005) 65 (9_Supplement): 935.

Published: 01 May 2005

View article

Journal Articles

Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line

Clara Ricci, Barbara Scappini, Vladimir Divoky, Simona Gatto, Francesco Onida, Srdan Verstovsek, Hagop M. Kantarjian, Miloslav Beran

Cancer Res (2002) 62 (21): 5995–5998.

Published: 01 November 2002

View article

Journal Articles

Tumoricidal Activation of Murine Resident Peritoneal Macrophages by Interleukin 2 and Tumor Necrosis Factor α

Srdan Verstovsek, Darbie Maccubbin, M. Jane Ehrke, Enrico Mihich

Cancer Res (1992) 52 (14): 3880–3885.

Published: 01 July 1992

View article

NARROW

Abstract LB108: Addition of navitoclax to ruxolitinib mediates responses suggestive of disease modification in patients with myelofibrosis previously treated with ruxolitinib monotherapy

Abstract CT216: A Phase 1/2 Study of INCB000928 as Monotherapy or in Combination with Ruxolitinib in Patients with Anemia Due to Myelofibrosis (INCB 00928-104)

Abstract 2915: Preclinical characterization of PRT543, a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5), with broad antitumor activity in in vitro and in vivo models

Abstract 4912: A snapshot of myeloproliferative neoplasms in the United States: Analysis of the “myMPN” patient registry

Abstract 3836: Efficacy of CDK9 inhibitor-based combinations as therapy for post-myeloproliferative neoplasm (MPN) secondary (s) AML

Abstract CT057: Phase 2, open-label, multicenter study to evaluate the efficacy and safety of INCB054828 in patients with myeloid/lymphoid neoplasms with fibroblast growth factor receptor 1 (FGFR1) rearrangement

Abstract 5067: BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells

Abstract 3205: Defining the immune checkpoint landscape of acute myeloid leukemia (AML)

Abstract 4699: Superior lethal activity of single agent BET protein PROTAC compared to bromodomain inhibitor or in combination with JAK inhibitor against post-myelofibrosis secondary AML cells

Bone Marrow Stroma–Secreted Cytokines Protect JAK2^V617F-Mutated Cells from the Effects of a JAK2 Inhibitor

Genetic Analysis of Transforming Events That Convert Chronic Myeloproliferative Neoplasms to Leukemias

Structure-based drug design of c-kit inhibitors for use in the treatment of several types of cancer

Expression analysis of the p15^INK4B and p21^Cip/WAF genes in patients with MDS treated with decitabine

EXEL-0862, a novel tyrosine kinase inhibitor, inhibits KIT activation and induces apoptosis in human mast cells bearing mutated codon 816 c-kit in vitro and ex vivo: Therapeutic implications

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has significant activity in adult patients (pts) with imatinib-resistant bcr-abl positive chronic myeloid leukemia (CML)

Cloretazine™, a novel sulfonylhydrazine alkylating agent, combined with cytarabine is an active regimen in patients with refractory hematologic malignancies

Mutation in the ATP-binding Pocket of the ABL Kinase Domain in an STI571-resistant BCR/ABL-positive Cell Line

Tumoricidal Activation of Murine Resident Peritoneal Macrophages by Interleukin 2 and Tumor Necrosis Factor α

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only